Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,738

The DOI matches its Crossref record.

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

Open access
O’Brien, M.E.R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D.G., Tomczak, P., Ackland, S.P., Orlandi, F., Mellars, L., Alland, L., Tendler, C.·2004·Annals of Oncology
DOI 10.1093/annonc/mdh097
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdh097

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 23

  1. 1998, Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group, Lancet, 352, 930, 10.1016/S0140-6736(98)03301-7 · DOI · Paper page
  2. Joensuu, 1998, Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial, J Clin Oncol, 16, 3720, 10.1200/JCO.1998.16.12.3720 · DOI
  3. Chlebowski, 1989, Combination versus sequential single agent chemotherapy in advanced breast cancer: associations with metastatic sites and long-term survival. The Western Cancer Study Group and The Southeastern Cancer Study Group, Br J Cancer, 59, 227, 10.1038/bjc.1989.46 · doi:10.1038/bjc.1989.46
  4. Smith, 1996, New treatments for breast cancer, Semin Oncol, 23, 506
  5. Symon, 1999, Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes, Cancer, 86, 72, 10.1002/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.0.CO;2-1 · DOI · Paper page
  6. Gordon, 2001, Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan, J Clin Oncol, 19, 3312, 10.1200/JCO.2001.19.14.3312 · DOI · Paper page
  7. Gabizon, 1997, Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours, Drugs, 54, 15, 10.2165/00003495-199700544-00005 · DOI · Paper page
  8. Ranson, 1997, Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial, J Clin Oncol, 15, 3185, 10.1200/JCO.1997.15.10.3185 · DOI · Paper page
  9. Miller, 1981, Reporting results of cancer treatment, Cancer, 47, 207, 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 · DOI · Paper page
  10. Singal, 1998, Doxorubicin-induced cardiomyopathy, N Engl J Med, 339, 900, 10.1056/NEJM199809243391307 · DOI · Paper page
  11. Von Hoff, 1979, Risk factors for doxorubicin-induced congestive heart failure, Ann Intern Med, 91, 710, 10.7326/0003-4819-91-5-710 · DOI · Paper page
  12. Titgan, 1997, Prevention of palmar-plantar erythrodysesthesia associated with liposome-encapsulated doxorubicin (Doxil) by oral dexamethasone, Proc Am Soc Clin Oncol, 16, 288a
  13. Vail, 1998, Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model, Clin Cancer Res, 4, 1567
  14. Honecker, 2002, Reduction of skin toxicity of pegylated lipsomal doxorubicin (PLD) by concomitant administration of dexamethasone and pyridoxine (PYR) in patients (PTS) with anthracycline-sensitive malignancies: a phase I/II trial, J Cancer Res Clin Oncol, 128, 848
  15. Baas, 2000, Caelyx in malignant mesothelioma: a phase II EORTC study, Ann Oncol, 11, 697, 10.1023/A:1008346925273 · doi:10.1023/a:1008346925273
  16. Israel, 2000, Phase II study of liposomal doxorubicin in advanced gynecologic cancers, Gynecol Oncol, 78, 143, 10.1006/gyno.2000.5819 · DOI
  17. Muggia, 2002, Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group Study, J Clin Oncol, 20, 2360, 10.1200/JCO.2002.08.171 · DOI · Paper page
  18. Safra, 2000, Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2, Ann Oncol, 11, 1029, 10.1023/A:1008365716693 · DOI · Paper page
  19. Torti, 1986, Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy, Cancer Res, 46, 3722
  20. Jain, 1985, A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer, J Clin Oncol, 3, 818, 10.1200/JCO.1985.3.6.818 · DOI
  21. Clin Oncol, 2000, Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment, J Clin Oncol, 18, 3115, 10.1200/JCO.2000.18.17.3115 · doi:10.1200/jco.2000.18.17.3115
  22. Harris, 2002, Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma, Cancer, 94, 25, 10.1002/cncr.10201 · DOI · Paper page
  23. Batist, 2001, Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer, J Clin Oncol, 19, 1444, 10.1200/JCO.2001.19.5.1444 · DOI · Paper page

Cited by

See all 1,738

Metadata

Authors
O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., Orlandi, F., Mellars, L., Alland, L., & Tendler, C.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2004-03
Volume
15
Issue
3
Pages
440-449
ISSN
0923-7534 (ISSN-L)
DOI
10.1093/annonc/mdh097
OpenAlex
W2096593771
Cited by
1,738
References
0
FWCI
28.09
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer. https://app.cochat.ai/papers/10.1093/annonc/mdh097
The paper
O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., Orlandi, F., Mellars, L., Alland, L., & Tendler, C. (2004). Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer. Annals of Oncology. https://doi.org/10.1093/annonc/mdh097

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.